查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1957532

2026年全球肿瘤辅助治疗市场报告

Oncology Adjuvants Global Market Report 2026
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

近年来，肿瘤辅助治疗市场经历了显着成长。预计该市场规模将从2025年的17.3亿美元成长至2026年的18.7亿美元，复合年增长率（CAGR）为8.2%。过去几年成长要素包括肿瘤辅助治疗药物供应有限、对化疗和放射线治疗的高度依赖、全球癌症发病率上升、辅助性治疗临床研究的进展以及肿瘤科医生对辅助治疗益处的认识不断提高。

预计未来几年肿瘤辅助治疗市场将维持强劲成长，2030年将达到25.4亿美元，复合年增长率（CAGR）为7.9%。预测期内的成长要素包括新型免疫疗法辅助药物的研发、标靶治疗方案的拓展、联合治疗的日益普及、精准医疗和基因组分析的整合，以及对肿瘤研究和临床试验投入的增加。预测期内的主要趋势包括免疫疗法和标靶治疗辅助药物的广泛应用、个人化癌症治疗方案的进一步整合、口服和皮下给药途径的拓展、多学科癌症治疗方法的兴起，以及对改善患者预后和减少治疗副作用的重视。

日益增长的个人化医疗需求预计将推动辅助肿瘤治疗市场的成长。个人化医疗是一种利用个人基因谱和生活方式因素来客製化治疗和照护的医疗框架。其兴起得益于基因和分子分析技术的进步，这些技术能够根据个体的生物学特征量身定制治疗方案，从而获得更好的疗效并减少副作用。辅助肿瘤治疗透过基于患者的基因资讯和肿瘤特征进行个人化辅助癌症治疗，从而支持个人化医疗，有效清除残留癌细胞并抑制过度毒性。例如，根据美国个人化医疗联盟（PMC）2024年2月发布的报告，美国食品药物管理局（FDA）在2023年核准了16种针对罕见疾病患者的新型个人化疗法，是2022年批准的6种疗法的两倍。因此，对个人化医疗日益增长的需求正在推动辅助性治疗市场的发展。

肿瘤辅助治疗市场的主要企业正透过免疫查核点抑制剂辅助性治疗等先进方法进行创新。该疗法旨在透过激活人体自身对抗残留癌细胞的防御机制，增强术后治疗效果并提高患者存活率。免疫查核点抑制剂辅助性治疗使用能够抑制PD-1、PD-L1和CTLA-4等通常抑制免疫活性的蛋白质的药物。例如，2023年1月，美国大型製药公司默克推出了获得FDA核准的辅助性治疗Keytruda（Pembrolizumab）。此药物用于接受铂类化疗后，IB期（T2a≥4 cm）、II期或IIIA期非小细胞肺癌（NSCLC）患者的治疗。 Keytruda（Pembrolizumab）透过靶向PD-1受体，实现精准的免疫查核点抑制，从而重新激活免疫系统识别和清除癌细胞的能力。 Keytruda是一种强效的非小细胞肺癌术后及化疗后化疗方案，可显着降低復发风险并延长存活期。此外，Keytruda利用患者特异性的免疫动力学，推动个人化癌症治疗的发展，巩固了其在现代免疫肿瘤学中的地位。

目录

第一章执行摘要

第二章 市场特征

  • 市场定义和范围
  • 市场区隔
  • 主要产品和服务概述
  • 全球肿瘤辅助治疗市场：吸引力评分及分析
  • 成长潜力分析、竞争评估、策略适宜性评估、风险状况评估

第三章 市场供应链分析

  • 供应链与生态系概述
  • 清单：主要原料、资源和供应商
  • 主要经销商和通路合作伙伴名单
  • 主要最终用户列表

第四章：全球市场趋势与策略

  • 关键科技与未来趋势
    • 生物技术、基因组学和精准医疗
    • 数位化、云端运算、巨量资料、网路安全
    • 人工智慧（AI）和自主人工智慧
    • 工业4.0和智慧製造
    • 物联网、智慧基础设施、互联生态系统
  • 主要趋势
    • 免疫疗法和标靶治疗辅助剂的使用增加
    • 个人化癌症治疗方案的整合正在取得进展。
    • 扩大口服和皮下给药途径
    • 多方面癌症治疗方法的发展
    • 致力于改善患者治疗效果并减少治疗副作用。

第五章 终端用户产业市场分析

  • 癌症研究机构
  • 癌症专科医院
  • 专科肿瘤诊所
  • 学术和研究机构
  • 临床试验中心

第六章 市场：宏观经济情景，包括利率、通货膨胀、地缘政治、贸易战和关税的影响、关税战和贸易保护主义对供应链的影响，以及 COVID-19 疫情对市场的影响。

第七章：全球策略分析架构、目前市场规模、市场对比及成长率分析

  • 全球肿瘤辅助治疗市场：PESTEL 分析（政治、社会、技术、环境、法律因素、驱动因素和限制因素）
  • 全球肿瘤辅助治疗市场规模、对比及成长率分析
  • 全球肿瘤辅助治疗市场表现：规模与成长，2020-2025年
  • 全球肿瘤辅助治疗市场预测：规模与成长，2025-2030年，2035年预测

第八章：全球市场总规模（TAM）

第九章 市场细分

  • 按补充剂类型
  • 化疗辅助药物、放射线治疗辅助药物、免疫疗法辅助药物、荷尔蒙疗法辅助药物、标靶治疗辅助药物
  • 透过行政途径
  • 口服、静脉注射、皮下注射、局部、肌肉注射
  • 指示
  • 乳癌、胶质母细胞瘤、肺癌、大肠直肠癌、卵巢癌、肉瘤、摄护腺癌及其他适应症
  • 最终用户
  • 癌症研究所，癌症专科医院
  • 依类型细分：化疗辅助药物
  • 烷化剂、抗代谢物、葱环类抗生素、植物生物碱、拓朴异构酶抑制剂、铂化合物等。
  • 按类型细分：辅助性治疗
  • 放射增敏剂、放射防护剂、乏氧细胞增敏剂、去氧核糖核酸(DNA) 修復抑制剂、免疫调节剂与辐射合併使用
  • 按类型细分：免疫疗法佐剂
  • 查核点抑制剂、细胞激素、癌症疫苗、过继性细胞移植、免疫调节剂
  • 按类型细分：荷尔蒙辅助性治疗
  • 选择性雌激素受体调节、Aromatase抑制剂、促性腺激素分泌释放激素促效剂或拮抗剂、雄性激素受体抑制剂、雌激素受体稳压器
  • 按类型细分：标靶治疗的辅助治疗
  • 蛋白酪氨酸激酶抑制剂（TKIs）、蛋白酶体抑制剂、聚（ADP-核糖）聚合酵素（PARP）抑制剂、mTOR抑制剂、v-Raf小鼠肉瘤病毒癌基因同源物B（BRAF）或丝裂原活化蛋白激酶激酶（MEK）抑制剂、血管内皮生长因子（VEGF）抑制剂

第十章 区域与国别分析

  • 全球肿瘤辅助治疗市场：依地区划分，历史资料及预测（2020-2025年、2025-2030年、2035年）
  • 全球肿瘤辅助治疗市场：依国家划分，历史资料及预测，2020-2025年、2025-2030年、2035年

第十一章 亚太市场

第十二章：中国市场

第十三章：印度市场

第十四章：日本市场

第十五章：澳洲市场

第十六章：印尼市场

第十七章：韩国市场

第十八章 台湾市场

第十九章 东南亚市场

第20章 西欧市场

第21章英国市场

第22章：德国市场

第23章：法国市场

第24章：义大利市场

第25章：西班牙市场

第26章：东欧市场

第27章：俄罗斯市场

第28章 北美市场

第29章：美国市场

第三十章：加拿大市场

第31章：南美市场

第32章：巴西市场

第33章 中东市场

第34章：非洲市场

第三十五章 市场监理与投资环境

第36章：竞争格局与公司概况

  • 肿瘤辅助治疗市场：竞争格局及市场占有率（2024年）
  • 肿瘤辅助治疗市场：公司估值矩阵
  • 肿瘤辅助治疗市场：公司概况
    • Pfizer Inc.
    • Johnson And Johnson
    • Roche Holding AG
    • Merck And Co. Inc.
    • Bayer AG

第37章 其他大型企业和创新企业

  • Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Amgen Inc., Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Ipsen SA, Jiangsu Hengrui Pharmaceuticals Co. Ltd., Croda International Plc, Dynavax Technologies Corporation, Agenus Inc., Elicio Therapeutics Inc.

第38章：全球市场竞争基准分析与仪錶板

第39章 重大併购

第四十章：高潜力市场国家、细分市场与策略

  • 2030年肿瘤辅助治疗市场：提供新机会的国家
  • 2030年肿瘤辅助治疗市场：蕴藏新机会的细分市场
  • 2030年肿瘤辅助治疗市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手的策略

第41章附录

简介目录
Product Code: PH4MOADJ01_G26Q1

Oncology adjuvants are substances or therapies administered alongside primary cancer treatments to enhance therapeutic effectiveness, reduce side effects, and improve patient outcomes. These adjuvants work by boosting the immune response, mitigating tumor resistance, or aiding in symptom management, thereby supporting a more comprehensive and personalized approach to cancer care.

The main types of oncology adjuvants include chemotherapy adjuvants, radiation adjuvants, immunotherapy adjuvants, hormonal adjuvants, and targeted therapy adjuvants. Chemotherapy adjuvants consist of drugs or compounds used in conjunction with primary chemotherapy to increase efficacy, reduce adverse effects, or enhance the patient's response to treatment. Oncology adjuvants are administered through various routes, including oral, intravenous, subcutaneous, topical, and intramuscular delivery. They are applied across multiple indications, such as breast cancer, glioblastoma, lung cancer, colorectal cancer, ovarian cancer, sarcoma, and prostate cancer, and serve a range of end users, including cancer hospitals, oncology clinics, and research institutions focused on cancer therapeutics.

Tariffs have impacted the oncology adjuvants market by increasing costs of imported biologics, chemotherapy adjuvants, and advanced immunotherapy agents. Segments such as immunotherapy adjuvants and targeted therapy adjuvants are most affected, with North America and Europe relying heavily on imports from Asia-Pacific regions like China and India. This has increased treatment costs and caused potential delays in therapy availability. On the positive side, tariffs have encouraged local production, research, and development of cost-optimized adjuvant therapies.

The oncology adjuvants market research report is one of a series of new reports from The Business Research Company that provides oncology adjuvants market statistics, including oncology adjuvants industry global market size, regional shares, competitors with a oncology adjuvants market share, detailed oncology adjuvants market segments, market trends and opportunities, and any further data you may need to thrive in the oncology adjuvants industry. This oncology adjuvants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The oncology adjuvants market size has grown strongly in recent years. It will grow from $1.73 billion in 2025 to $1.87 billion in 2026 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to limited availability of oncology adjuvants, reliance on chemotherapy and radiation as primary treatments, growing cancer incidence globally, increasing clinical research on adjuvant therapies, awareness of adjuvant benefits among oncologists.

The oncology adjuvants market size is expected to see strong growth in the next few years. It will grow to $2.54 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to development of novel immunotherapy adjuvants, expansion of targeted therapy options, increasing adoption of combination therapy approaches, integration of precision medicine and genomic profiling, rising investment in oncology research and clinical trials. Major trends in the forecast period include rising adoption of immunotherapy and targeted therapy adjuvants, increased integration of personalized cancer treatment plans, expansion of oral and subcutaneous administration routes, growth in multi-modal cancer treatment approaches, focus on enhancing patient outcomes and reducing therapy side effects.

The growing need for personalized medicine is set to boost the oncology adjuvants market ahead. Personalized medicine is a healthcare framework that leverages a person's genetic profile and lifestyle factors to customize treatments and care. Its rise stems from strides in genetic and molecular analysis, facilitating therapies matched to an individual's biology for better results and fewer side effects. Oncology adjuvants support personalized medicine by enabling tailored supplemental cancer therapies based on a patient's genetics and tumor traits, effectively hitting leftover cancer cells while curbing excess toxicity. For example, in February 2024, the Personalized Medicine Coalition (PMC), a US organization, reported that the FDA approved 16 novel personalized therapies for rare disease patients in 2023, doubling from 6 in 2022. Thus, the rising demand for personalized medicine is fueling the oncology adjuvants market.

Leading companies in the oncology adjuvants market are innovating with advanced approaches like immune checkpoint inhibitor adjuvant therapy to amplify post-surgery outcomes and boost patient survival by activating the body's defenses against lingering tumor cells. Immune checkpoint inhibitor adjuvant therapy involves medications that disrupt proteins like PD-1, PD-L1, or CTLA-4, which typically restrain immune activity. For instance, in January 2023, Merck & Co., Inc., a US pharmaceutical leader, introduced KEYTRUDA (pembrolizumab) as an FDA-approved adjuvant regimen. It comes after surgery and platinum chemotherapy for Stage IB (T2a >=4 cm), II, or IIIA non-small cell lung cancer (NSCLC). KEYTRUDA (pembrolizumab) delivers precise immune checkpoint blockade by targeting the PD-1 receptor, reawakening the immune system's capacity to recognize and eliminate cancer cells. It offers a potent post-surgical and chemo option for NSCLC patients, slashing recurrence risks and extending survival. Moreover, KEYTRUDA advances individualized oncology by tapping into patient-specific immune dynamics, cementing its role in contemporary immuno-oncology.

In January 2024, Transgene S.A., a France-based healthcare tech firm, teamed up with NEC Corporation to pioneer robotic-assisted medical tools. Through this alliance, Transgene and NEC intend to sharpen procedure precision, streamline operations, and elevate patient results by merging Transgene's therapy expertise with NEC's AI, 5G, and imaging prowess-enhancing workflows, aiding instant clinical choices, and expanding access to sophisticated care. NEC Corporation is a Japan-based tech giant excelling in IT, communications, and AI-powered imaging for healthcare and business uses.

Major companies operating in the oncology adjuvants market are Pfizer Inc., Johnson And Johnson, Roche Holding AG, Merck And Co. Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Amgen Inc., Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Ipsen S.A., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Croda International Plc, Dynavax Technologies Corporation, Agenus Inc., Elicio Therapeutics Inc.

North America was the largest region in the oncology adjuvants market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the oncology adjuvants market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the oncology adjuvants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The oncology adjuvants market consists of revenues earned by entities by providing services such as treatment enhancement, side effect reduction, tumor resistance prevention, and personalized therapy optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The oncology adjuvants market also includes sales of nutritional adjuvants, gene therapy adjuvants, oncolytic virus adjuvants, and hyperthermia adjuvants. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Oncology Adjuvants Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses oncology adjuvants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for oncology adjuvants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The oncology adjuvants market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Type Of Adjuvant: Chemotherapy Adjuvants; Radiation Adjuvants; Immunotherapy Adjuvants; Hormonal Adjuvants; Targeted Therapy Adjuvants
  • 2) By Administration Route: Oral; Intravenous; Subcutaneous; Topical; Intramuscular
  • 3) By Indication: Breast Cancer; Glioblastoma; Lung Cancer; Colorectal Cancer; Ovarian Cancer; Sarcoma; Prostate Cancer; Other Indications
  • 4) By End User: Cancer Research Institute; Cancer Hospitals
  • Subsegments:
  • 1) By Chemotherapy Adjuvants: Alkylating Agents; Antimetabolites; Anthracyclines; Plant Alkaloids; Topoisomerase Inhibitors; Platinum-Based Compounds; Others
  • 2) By Radiation Adjuvants: Radiosensitizers; Radioprotectors; Hypoxic Cell Sensitizers; Deoxyribonucleic Acid (DNA) Repair Inhibitors; Immune Modulating Agents Combined With Radiation
  • 3) By Immunotherapy Adjuvants: Checkpoint Inhibitors; Cytokines; Cancer Vaccines; Adoptive Cell Transfer; Immune Modulating Agents
  • 4) By Hormonal Adjuvants: Selective Estrogen Receptor Modulators; Aromatase Inhibitors; Gonadotropin-Releasing Hormone Agonists Or Antagonists; Androgen Receptor Inhibitors; Estrogen Receptor Downregulators
  • 5) By Targeted Therapy Adjuvants: Tyrosine Kinase Inhibitors (TKIs); Proteasome Inhibitors; Poly (ADP-Ribose) Polymerase (PARP) Inhibitors; mTOR Inhibitors; v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) Or Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors; Vascular Endothelial Growth Factor (VEGF) Inhibitors
  • Companies Mentioned: Pfizer Inc.; Johnson And Johnson; Roche Holding AG; Merck And Co. Inc.; Bayer AG; Bristol-Myers Squibb Company; AstraZeneca PLC; Novartis AG; Eli Lilly And Company; Amgen Inc.; Regeneron Pharmaceuticals; Daiichi Sankyo Company Limited; Ipsen S.A.; Jiangsu Hengrui Pharmaceuticals Co. Ltd.; Croda International Plc; Dynavax Technologies Corporation; Agenus Inc.; Elicio Therapeutics Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Oncology Adjuvants Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Oncology Adjuvants Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Oncology Adjuvants Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Oncology Adjuvants Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.3 Artificial Intelligence & Autonomous Intelligence
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Rising Adoption Of Immunotherapy And Targeted Therapy Adjuvants
    • 4.2.2 Increased Integration Of Personalized Cancer Treatment Plans
    • 4.2.3 Expansion Of Oral And Subcutaneous Administration Routes
    • 4.2.4 Growth In Multi-Modal Cancer Treatment Approaches
    • 4.2.5 Focus On Enhancing Patient Outcomes And Reducing Therapy Side Effects

5. Oncology Adjuvants Market Analysis Of End Use Industries

  • 5.1 Cancer Research Institutes
  • 5.2 Cancer Hospitals
  • 5.3 Specialty Oncology Clinics
  • 5.4 Academic And Research Laboratories
  • 5.5 Clinical Trial Centers

6. Oncology Adjuvants Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Oncology Adjuvants Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Oncology Adjuvants PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Oncology Adjuvants Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Oncology Adjuvants Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Oncology Adjuvants Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Oncology Adjuvants Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Oncology Adjuvants Market Segmentation

  • 9.1. Global Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Chemotherapy Adjuvants, Radiation Adjuvants, Immunotherapy Adjuvants, Hormonal Adjuvants, Targeted Therapy Adjuvants
  • 9.2. Global Oncology Adjuvants Market, Segmentation By Administration Route, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Oral, Intravenous, Subcutaneous, Topical, Intramuscular
  • 9.3. Global Oncology Adjuvants Market, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Breast Cancer, Glioblastoma, Lung Cancer, Colorectal Cancer, Ovarian Cancer, Sarcoma, Prostate Cancer, Other Indications
  • 9.4. Global Oncology Adjuvants Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cancer Research Institute, Cancer Hospitals
  • 9.5. Global Oncology Adjuvants Market, Sub-Segmentation Of Chemotherapy Adjuvants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Alkylating Agents, Antimetabolites, Anthracyclines, Plant Alkaloids, Topoisomerase Inhibitors, Platinum-Based Compounds, Others
  • 9.6. Global Oncology Adjuvants Market, Sub-Segmentation Of Radiation Adjuvants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Radiosensitizers, Radioprotectors, Hypoxic Cell Sensitizers, Deoxyribonucleic Acid (DNA) Repair Inhibitors, Immune Modulating Agents Combined With Radiation
  • 9.7. Global Oncology Adjuvants Market, Sub-Segmentation Of Immunotherapy Adjuvants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Adoptive Cell Transfer, Immune Modulating Agents
  • 9.8. Global Oncology Adjuvants Market, Sub-Segmentation Of Hormonal Adjuvants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Selective Estrogen Receptor Modulators, Aromatase Inhibitors, Gonadotropin-Releasing Hormone Agonists Or Antagonists, Androgen Receptor Inhibitors, Estrogen Receptor Downregulators
  • 9.9. Global Oncology Adjuvants Market, Sub-Segmentation Of Targeted Therapy Adjuvants, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Tyrosine Kinase Inhibitors (TKIs), Proteasome Inhibitors, Poly (ADP-Ribose) Polymerase (PARP) Inhibitors, mTOR Inhibitors, v-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) Or Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors, Vascular Endothelial Growth Factor (VEGF) Inhibitors

10. Oncology Adjuvants Market Regional And Country Analysis

  • 10.1. Global Oncology Adjuvants Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Oncology Adjuvants Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Oncology Adjuvants Market

  • 11.1. Asia-Pacific Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Oncology Adjuvants Market

  • 12.1. China Oncology Adjuvants Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Oncology Adjuvants Market

  • 13.1. India Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Oncology Adjuvants Market

  • 14.1. Japan Oncology Adjuvants Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Oncology Adjuvants Market

  • 15.1. Australia Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Oncology Adjuvants Market

  • 16.1. Indonesia Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Oncology Adjuvants Market

  • 17.1. South Korea Oncology Adjuvants Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Oncology Adjuvants Market

  • 18.1. Taiwan Oncology Adjuvants Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Oncology Adjuvants Market

  • 19.1. South East Asia Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Oncology Adjuvants Market

  • 20.1. Western Europe Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Oncology Adjuvants Market

  • 21.1. UK Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Oncology Adjuvants Market

  • 22.1. Germany Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Oncology Adjuvants Market

  • 23.1. France Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Oncology Adjuvants Market

  • 24.1. Italy Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Oncology Adjuvants Market

  • 25.1. Spain Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Oncology Adjuvants Market

  • 26.1. Eastern Europe Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Oncology Adjuvants Market

  • 27.1. Russia Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Oncology Adjuvants Market

  • 28.1. North America Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Oncology Adjuvants Market

  • 29.1. USA Oncology Adjuvants Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Oncology Adjuvants Market

  • 30.1. Canada Oncology Adjuvants Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Oncology Adjuvants Market

  • 31.1. South America Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Oncology Adjuvants Market

  • 32.1. Brazil Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Oncology Adjuvants Market

  • 33.1. Middle East Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Oncology Adjuvants Market

  • 34.1. Africa Oncology Adjuvants Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Oncology Adjuvants Market, Segmentation By Type Of Adjuvant, Segmentation By Administration Route, Segmentation By Indication, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Oncology Adjuvants Market Regulatory and Investment Landscape

36. Oncology Adjuvants Market Competitive Landscape And Company Profiles

  • 36.1. Oncology Adjuvants Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Oncology Adjuvants Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Oncology Adjuvants Market Company Profiles
    • 36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

37. Oncology Adjuvants Market Other Major And Innovative Companies

  • Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Eli Lilly And Company, Amgen Inc., Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Ipsen S.A., Jiangsu Hengrui Pharmaceuticals Co. Ltd., Croda International Plc, Dynavax Technologies Corporation, Agenus Inc., Elicio Therapeutics Inc.

38. Global Oncology Adjuvants Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Oncology Adjuvants Market

40. Oncology Adjuvants Market High Potential Countries, Segments and Strategies

  • 40.1 Oncology Adjuvants Market In 2030 - Countries Offering Most New Opportunities
  • 40.2 Oncology Adjuvants Market In 2030 - Segments Offering Most New Opportunities
  • 40.3 Oncology Adjuvants Market In 2030 - Growth Strategies
    • 40.3.1 Market Trend Based Strategies
    • 40.3.2 Competitor Strategies

41. Appendix

  • 41.1. Abbreviations
  • 41.2. Currencies
  • 41.3. Historic And Forecast Inflation Rates
  • 41.4. Research Inquiries
  • 41.5. The Business Research Company
  • 41.6. Copyright And Disclaimer